MedPath

The examination of the efficacy by adverse reaction changing the treatment with Oxybutynin or Mirabegron on the patient who cannot go on treatment with anticholinergic agent

Not Applicable
Conditions
Overactive bladder
Registration Number
JPRN-UMIN000019736
Lead Sponsor
Department of Urology, Shiga University of medical science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
15
Inclusion Criteria

Not provided

Exclusion Criteria

contraindication of the medicine acute urinary retension within 12 months residual urine over 100mL urinary infection a1 blacker within 4 weeks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath